Back to Search Start Over

Impact of Nucleic Acid Amplification Test on Clinical Outcomes in Patients with Clostridioides difficile Infection.

Authors :
Yamada Y
Miyazaki M
Kushima H
Komiya Y
Nakashima A
Ishii H
Imakyure O
Source :
Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2023 Feb 21; Vol. 12 (3). Date of Electronic Publication: 2023 Feb 21.
Publication Year :
2023

Abstract

A nucleic acid amplification test (NAAT) is recommended to determine whether or not patients have a Clostridioides difficile infection (CDI) when the glutamate dehydrogenase activity assay is positive and the rapid membrane enzyme immunoassays for toxins is negative. In our hospital, a NAAT was introduced to diagnose CDI precisely in April 2020. This study aimed to investigate the impact of a NAAT on the clinical outcomes in patients with CDI at our hospital. Seventy-one patients diagnosed with CDI between April 2017 and March 2022 were included in our study. Patients with CDI were divided into two groups: before (pre-NAAT) and after (post-NAAT) the introduction of NAAT. The clinical outcome was compared between the two groups. Of the 71 patients with CDI, 41 were sorted into the pre-NAAT group and 30 into the post-NAAT group. The clinical cure rate was significantly higher in the post-NAAT group compared to the pre-NAAT group (76.7% vs. 48.8%, p = 0.018). In the multivariable analysis, the clinical cure was significantly associated with the introduction of NAAT ( p = 0.022). Our findings suggest that the introduction of NAAT can improve the clinical outcomes in CDI patients.

Details

Language :
English
ISSN :
2079-6382
Volume :
12
Issue :
3
Database :
MEDLINE
Journal :
Antibiotics (Basel, Switzerland)
Publication Type :
Academic Journal
Accession number :
36978295
Full Text :
https://doi.org/10.3390/antibiotics12030428